How drugmakers became masters at producing authorized generics

When PDL BioPharma ’s $40 million blood-pressure medicine faced the threat of a generic rival this year, the company pulled out a little-known strategy that critics say helps keep drugs expensive and competition weak. It launched its own generic version of Tekturna, a pill taken daily by thousands. PDL’s “author ized” copycat hit the market in March, […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.

Source: Kevin, M.D. - Medical Weblog - August 14, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/jay-hancock-and-sydney-lupkin" rel="tag" > Jay Hancock  and Sydney Lupkin < /a > < /span > Tags: Meds Medications Source Type: blogs